Pathophysiology, Genetics & Classification

Question	Answer
1. What is the fundamental molecular abnormality characterizing the pathogenesis of IgA Vasculitis (IgAV)?	The core molecular defect is the abnormal production of galactose-deficient IgA1 (Gd-IgA1) molecules, which escape hepatic clearance and form pathogenic circulating immune complexes.
2. How do galactose-deficient IgA1 molecules trigger tissue injury in IgAV?	Aberrantly glycosylated IgA1 molecules expose terminal N-acetylgalactosamine residues, which are recognized by circulating autoantibodies (mainly IgG or IgA), forming nephritogenic immune complexes that deposit in small vessel walls.
3. What is the primary immunopathological mechanism operating within the renal glomeruli during IgAV nephritis?	Mesangial deposition of polymeric IgA1 and Gd-IgA1 triggers the alternative complement pathway activation, leading to local complement consumption, C3 deposition, leukocyte infiltration, and cytokine-mediated glomerular damage.
4. What are the key genetic associations identified in children with IgAV susceptibility and disease severity?	Genetic susceptibility is strongly linked to polymorphisms within the MHC class II region (specifically HLA-DRB1) and genes regulating the complement pathway (like CFHR1-CFHR3 deletions).
5. What is the cellular histopathology seen in the microvasculature during an acute cutaneous lesion of IgAV?	Skin biopsies reveal a classic leukocytoclastic vasculitis characterized by neutrophil infiltration within and around dermal post-capillary venules, accompanied by fibrinoid necrosis and nuclear debris (dust).
6. According to the EULAR/PRINTO/PRES consensus criteria, what is the mandatory clinical feature required to diagnose IgAV?	The mandatory criterion is palpable purpura (or petechiae) with lower limb predominance, occurring in the presence of a normal platelet count.
7. Beyond the mandatory cutaneous lesion, what additional features are required by EULAR/PRINTO/PRES criteria to confirm IgAV?	At least one of the following must be present: diffuse abdominal pain, biopsy showing predominant IgA deposition in tissues, acute arthritis or arthralgia, or renal involvement (hematuria/proteinuria).
8. What anatomical vascular bed is predominantly targeted by immune complex deposition in IgAV?	IgAV specifically targets the microvasculature, primarily post-capillary venules, alongside capillaries and arterioles located in the skin, gut, joints, and kidneys.
9. What is the International Study of Kidney Disease in Children (ISKDC) histological staging system based upon?	The ISKDC grading is based strictly on the percentage of glomeruli exhibiting cellular or fibrocellular crescents on light microscopy, ranging from Grade I to Grade VI.
10. What defines ISKDC Grade IIIa versus Grade IIIb in HSP nephritis?	Both exhibit mesangial proliferation with crescents in less than 50% of glomeruli, but Grade IIIa indicates focal involvement (less than 50% of glomeruli affected), whereas Grade IIIb indicates diffuse involvement (50% or more glomeruli affected).
11. What renal histopathology distinguishes ISKDC Grade V from lower grades?	ISKDC Grade V is characterized by mesangial proliferation with crescents present in greater than 75% of glomeruli, presenting clinically as rapidly progressive glomerulonephritis (RPGN).
12. What temporal window dictates the absolute necessity for long-term renal monitoring in children with IgAV?	Approximately 90% of renal involvement manifests within the first 6 to 8 weeks following the initial onset of systemic symptoms, mandating structured urinalysis surveillance up to 6 months.
13. Why are mucosal bleeding manifestations characteristically absent in uncomplicated IgAV despite petechiae?	Unlike thrombocytopenic purpura where platelet counts are profoundly low, IgAV is a non-thrombocytopenic purpura where platelet counts are normal or elevated, preserving primary hemostasis.
14. What mechanical factor dictates the gravity-dependent distribution of palpable purpura across the lower extremities and buttocks?	Increased hydrostatic pressure within dependent microvessels promotes localized shear stress and endothelial activation, facilitating the deposition of circulating Gd-IgA1 immune complexes.
15. What pathophysiological mechanism accounts for the characteristic colicky periumbilical abdominal pain in IgAV?	Submucosal IgA immune complex deposition induces localized vasculitis, edema, hemorrhage, and ischemia within the walls of the small and large intestines, carrying a risk of intussusception.
16. Why do joint manifestations in IgAV follow an oligoarticular, non-erosive pattern without causing long-term deformity?	Joint swelling is driven by periarticular soft tissue edema and transient synovial inflammation secondary to immune complex localization, rather than chronic synovial destruction or cartilage erosion.
17. What cellular cytokine cascade is primarily responsible for mesangial cell activation and proliferation in IgAN and IgAV nephritis?	Deposited polymeric IgA1 stimulates mesangial cells to secrete pro-inflammatory cytokines (such as IL-6, TNF-alpha) and growth factors (such as TGF-beta and PDGF), driving extracellular matrix expansion.
18. VIVA TRAP: Can a definitive diagnosis of IgA Vasculitis be established in the presence of thrombocytopenia?	NEVER. By definition, IgA Vasculitis is a non-thrombocytopenic purpura; if significant thrombocytopenia or coagulopathy is present, alternative diagnoses such as immune thrombocytopenia or vasculitis secondary to a systemic disorder must be investigated.
19. What role does mucosal immunity play in the upstream pathophysiology of IgAV?	An abnormal mucosal immune response (often triggered by preceding upper respiratory or gastrointestinal infections) leads to mucosal hyper-reactivity and aberrant synthesis of galactose-deficient polymeric IgA1.
20. What is the clinical significance of macroscopic hematuria persisting beyond 4 weeks in an IgAV patient?	Persistent macroscopic hematuria serves as a strong clinical indicator of active glomerular inflammation, prompting the performance of a renal biopsy to rule out significant crescentic nephritis.

Clinical History & Bedside Evaluation

Question	Answer
1. What is the typical peak age of presentation for IgA Vasculitis in pediatric clinical practice?	IgA Vasculitis predominantly affects children aged 3 to 10 years, with a peak incidence seen between 4 and 6 years of age.
2. How does the age of onset in infants or adolescents alter the typical clinical trajectory of IgAV?	Infants under 2 years often present with prominent soft tissue edema of the scalp, hands, and feet, whereas adolescents frequently experience a more protracted course and higher risk of severe renal involvement.
3. What gender predilection is classically documented in pediatric epidemiological studies of IgA Vasculitis?	IgAV shows a clear male predilection, affecting boys nearly 1.5 to 2 times more frequently than girls.
4. What chronological prodromal history is typically elicited 1 to 3 weeks prior to the onset of purpura in IgAV?	A history of a preceding acute upper respiratory tract infection, most commonly pharyngitis or tonsillitis, is reported in 50 to 75% of children.
5. What specific dietary recall or antecedent gastrointestinal exposure must be actively inquired about to rule out post-infectious differentials?	A history of unpasteurized dairy consumption, undercooked meat, or bloody diarrhea is crucial to rule out Hemolytic Uremic Syndrome (HUS).
6. What essential elements of the perinatal and developmental history should be documented during a comprehensive IgAV evaluation?	A standard developmental and birth history is generally unremarkable in IgAV, but documenting baseline growth parameters helps monitor potential impacts of subsequent corticosteroid therapy.
7. How significant is a positive family pedigree or history of autoimmune disorders in a child presenting with IgAV?	Familial clustering is extremely rare; a positive family history of glomerulonephritis or hematuria should prompt consideration of inherited nephropathies like Alport syndrome or familial IgA nephropathy.
8. VIVA TRAP: Can you establish a diagnosis of IgA Vasculitis based solely on a positive family history of Henoch-Schönlein purpura?	NO. IgAV is a sporadic, acquired systemic vasculitis; family history plays virtually no diagnostic role and diagnosis relies entirely on clinical criteria.
9. What clinical red flag in the history differentiates straightforward IgAV joint pain from septic arthritis or acute rheumatic fever?	The presence of painful, non-migratory oligoarthritis primarily affecting large lower limb joints (ankles and knees) without periarticular erythema or permanent deformity points toward IgAV rather than suppuration or rheumatic fever.
10. What specific historical detail regarding abdominal pain warrants immediate surgical consultation in an IgAV patient?	Severe, paroxysmal, colicky abdominal pain accompanied by persistent vomiting and passage of red currant jelly stools indicates the critical risk of ileo-ileal intussusception.
11. What historical red flag in bedside urinalysis or fluid balance history signals impending acute kidney injury?	A history of rapidly diminishing urine output (oliguria), frothy urine, or gross dark-colored (cola-colored) urine points toward acute nephritis or crescent formation.
12. How does the physical bedside assessment of purpuric lesion distribution help differentiate IgAV from Immune Thrombocytopenic Purpura (ITP)?	In IgAV, lesions are strictly symmetrical and confined to gravity-dependent areas (buttocks and lower limbs), whereas ITP lesions are scattered randomly across the trunk, face, and upper body.
13. What bedside bedside maneuver confirms the non-blanching nature of the cutaneous lesions in IgAV?	Performing diascopy—pressing a clear glass slide or tongue depressor firmly against the purpuric lesion—demonstrates that the redness does not fade, confirming true extravasation of red blood cells.
14. What predisposing drug or vaccination history must be systematically explored when evaluating atypical purpuric eruptions?	A detailed medication and recent vaccination history must be reviewed to rule out drug-induced hypersensitivity vasculitis or adverse vaccine reactions mimicking IgAV.
15. Why is a meticulous bedside evaluation of blood pressure mandatory during the initial history and physical examination of an IgAV child?	Hypertension can develop abruptly secondary to acute glomerulonephritis and serves as an independent bedside marker for severe renal involvement requiring urgent intervention.
16. What key feature in the past medical history helps exclude systemic lupus erythematosus (SLE) in a child presenting with purpura and joint pains?	The absence of malar rash, photosensitivity, generalized lymphadenopathy, and serological multi-system cytopenias helps rule out childhood-onset SLE.
17. What specific feature in the history of the cutaneous rash distinguishes early acute lesions from resolving lesions during bedside rounds?	Early acute lesions are raised, palpable, and bright red-purple, whereas resolving lesions transition into flat, hyperpigmented brown macules before slowly fading.
18. What historical dietary or allergic antecedent is frequently blamed by parents but lacks proven pathophysiological causation in IgAV?	Parents frequently attribute the onset of purpura to specific food allergies or dietary indiscretions, which play no primary causative role in galactose-deficient IgA1 pathogenic cascades.
19. What critical bedside monitoring protocol must be explained to the parents regarding long-term recurrence risk upon discharge?	Parents must be counseled that up to one-third of children experience at least one recurrence of purpura and joint pain within the first few months, necessitating continued outpatient urine surveillance.

Physical Examination & Bedside Signs

Question	Answer
1. What anatomical distribution pattern of skin lesions must the examiner specifically look for to fulfill the primary diagnostic criteria for IgAV?	Symmetrical distribution concentrated over gravity-dependent extensor surfaces, predominantly the lower limbs (shins, ankles, dorsum of feet) and buttocks, with relative sparing of the face and trunk.
2. What specific bedside physical finding differentiates IgAV arthropathy from acute rheumatic fever or septic arthritis?	IgAV joint involvement presents as periarticular tenderness and soft tissue swelling of large lower limb joints (ankles and knees) that is characteristically non-migratory and non-deforming.
3. During abdominal palpation, what specific physical sign should the examiner elicit when evaluating a child with suspected gastrointestinal IgAV?	Colicky periumbilical tenderness reflecting submucosal edema and hemorrhage, while carefully screening for localized rebound tenderness or a sausage-shaped mass that suggests intussusception.
4. What essential anthropometric assessment must be performed on admission and daily during the bedside evaluation of an IgAV child with systemic involvement?	Daily weight measurement and strict fluid intake-output charting to monitor for occult fluid retention, oliguria, or the development of nephrotic-range edema.
5. What bedside inspection finding in the periorbital or dependent regions signals the onset of severe renal glomerular pathology?	Pitting dependent edema, particularly periorbital puffiness or scrotal/labial swelling, indicating significant proteinuria and hypoalbuminemia from nephrotic-range injury.
6. What specific physical examination maneuver must be performed to rule out scrotal involvement in male pediatric patients with IgAV?	Careful inspection and gentle palpation of the scrotum to check for acute testicular swelling, tenderness, or erythema, which mimics acute testicular torsion due to local vasculitis.
7. How should the examiner assess the peripheral capillary refill time and microvascular status in a child presenting with extensive lower limb purpura?	By checking peripheral pulses and capillary refill time in all four limbs to ensure that the purpuric process has not compromised macrovascular perfusion or caused ischemic neuropathy.
8. What bedside auscultatory sign over the abdomen requires immediate escalation of care in a child with severe gastrointestinal IgAV?	Hyperactive bowel sounds progressing to absent bowel sounds, which signify mechanical bowel obstruction or paralytic ileus secondary to severe bowel wall ischemia and intussusception.
9. What specific bedside dermatological sign helps distinguish older, resolving lesions from acute crops of purpura?	Older lesions fade into brownish-yellow or hyperpigmented macules due to hemosiderin deposition, whereas acute lesions remain bright red-purple and palpable.
10. What physical sign should the examiner actively search for in the oral cavity to rule out systemic vasculitides like Kawasaki disease or thrombocytopenic bleeding?	The examiner should inspect for oral mucosal ulcers, strawberry tongue, or wet purpura, all of which are characteristically absent in uncomplicated IgA Vasculitis.
11. What bedside evaluation technique is required to quantify lower limb joint effusion during the musculoskeletal examination?	Palpation for patellar tap or suprapatellar ballotment at the knee joint, and assessment of bogginess around the malleoli for ankle involvement.
12. What specific bedside neurological sign must be evaluated if a child with IgAV presents with sudden behavioral changes or severe headache?	Detailed fundoscopic examination and central nervous system assessment to rule out central nervous system vasculitis or malignant hypertension.
13. VIVA TRAP: Can you confirm the presence of clinically significant renal impairment in IgAV based solely on the absence of physical edema?	NO. Significant glomerular injury with microscopic hematuria and non-nephrotic proteinuria can be completely silent clinically without any visible edema or overt hypertension.
14. What specialized bedside sign can be elicited by gently stroking or scratching unaffected skin in patients with active cutaneous vasculitis?	The pathergy phenomenon can occasionally be demonstrated, though it is more classical in Behçet disease; in IgAV, new lesions may occasionally form along pressure or trauma lines (Koebner phenomenon).
15. How should the clinician inspect the characteristics of stool during bedside rounds when evaluating gastrointestinal involvement?	Visually inspecting diapers or stool samples for frank hematochezia, melena, or occult blood using bedside guaiac testing if gross bleeding is not immediately obvious.
16. What critical bedside sign indicates the potential development of severe peripheral neuropathy or mononeuritis multiplex in rare systemic variants?	Focal sensory loss, motor weakness, or asymmetrical diminished deep tendon reflexes in the lower extremities during neurological examination.

Diagnostic Criteria & Investigations

Question	Answer
1. What is the mandatory primary clinical criterion required by the EULAR/PRINTO/PRES 2010 consensus criteria to establish a diagnosis of IgA Vasculitis?	The mandatory criterion is palpable purpura, defined as raised, non-thrombocytopenic purpuric skin lesions with a predominant distribution over the lower limbs and buttocks.
2. What is the gold standard diagnostic laboratory test for demonstrating vascular IgA deposition when cutaneous lesions are atypical or atypical presentations occur?	A direct immunofluorescence (DIF) microscopy of a skin biopsy showing prominent IgA and C3 immune complex deposition within the walls of superficial dermal venules.
3. What characteristic platelet count range distinguishes IgA Vasculitis from Immune Thrombocytopenic Purpura (ITP) on routine automated complete blood counts?	Platelet counts in IgA Vasculitis are typically normal or elevated (thrombocytosis, often exceeding 400,000/µL as an acute phase response), whereas ITP demonstrates severe thrombocytopenia (<50,000/µL).
4. What specific urinary screening investigations must be performed at initial presentation and during follow-up to detect early HSP nephritis?	Serial urinalysis via dipstick and microscopic examination for red blood cells (microscopic hematuria) and urinary protein-to-creatinine ratio (UPCR) to detect proteinuria.
5. What specific laboratory cutoff value for urinary protein-to-creatinine ratio (UPCR) defines nephrotic-range proteinuria requiring renal biopsy in HSP nephritis?	Nephrotic-range proteinuria is defined as a UPCR >2.0 mg/mg (or urinary protein excretion >40 mg/m^2/hr).
6. According to ISPN 2023 guidelines, what is the precise proteinuria threshold for biopsy when persistent over several weeks?	A renal biopsy is indicated if persistent significant proteinuria demonstrates a UPCR between 0.5 and 1.0 mg/mg for more than 4 weeks despite conservative management.
7. What ISKDC histological grade defines severe crescentic glomerulonephritis where crescents involve 50% to 75% of total glomeruli?	Grade IV HSP nephritis, which requires intensive immunosuppressive therapy such as high-dose IV methylprednisolone combined with cyclophosphamide or MMF.
8. What imaging modality is considered the primary investigation of choice when a child with IgAV presents with severe colicky abdominal pain to rule out intussusception?	Ultrasonography of the abdomen, which typically demonstrates bowel wall thickening, edematous submucosa, target signs, and can reliably detect ileo-ileal intussusception.
9. What specific radiological finding on an abdominal ultrasound distinguishes uncomplicated HSP bowel wall edema from surgical intussusception?	Uncomplicated bowel involvement shows diffuse or segmental symmetrical mural thickening with hyperperfusion on Doppler, whereas intussusception reveals a classic concentric multi-layered target or pseudokidney sign with a trapped mesenteric lead point.
10. What serum biochemical marker is most critical to monitor alongside serum electrolytes and blood urea nitrogen to assess acute kidney injury in severe HSP nephritis?	Serum creatinine, which serves as the primary biochemical index to track estimated glomerular filtration rate (eGFR) and identify rapidly progressive glomerulonephritis.
11. What serum immunoglobulin level is frequently elevated in children with active IgA Vasculitis, though it is neither mandatory nor sufficiently sensitive for routine diagnosis?	Serum IgA levels are elevated in up to 50% of patients during the acute phase, but normal levels do not exclude the diagnosis.
12. How do serum complement levels (C3 and C4) typically behave in IgA Vasculitis, helping differentiate it from post-streptococcal glomerulonephritis or lupus nephritis?	Serum C3 and C4 levels are characteristically normal or elevated in IgA Vasculitis, whereas they are typically depressed in post-streptococcal acute glomerulonephritis and systemic lupus erythematosus.
13. What throat investigation should be performed given the strong epidemiological association between preceding upper respiratory infections and IgAV onset?	A throat swab for rapid antigen detection test (RADT) or throat culture for Group A Streptococcus, alongside anti-streptolysin O (ASO) titers.
14. What blood coagulation profile parameters (PT/INR and APTT) are typically documented during the diagnostic workup to rule out coagulopathic purpura?	Prothrombin Time (PT/INR) and Activated Partial Thromboplastin Time (APTT) are characteristically normal in IgA Vasculitis, helping rule out bleeding diathesias and disseminated intravascular coagulation.
15. VIVA TRAP: Can a normal initial urinalysis at presentation completely rule out the future development of renal involvement in a child with IgA Vasculitis?	NO. Over 90% of renal involvement develops within the first 6 to 8 weeks of illness, necessitating rigorous serial urinary surveillance even if the initial urinalysis is completely normal.
16. What specific duration of long-term renal surveillance protocol is recommended by pediatric nephrology guidelines following the onset of IgA Vasculitis?	Serial blood pressure and urinalysis monitoring must be maintained for at least 6 months post-onset to catch delayed-onset nephritis and prevent chronic kidney disease.
17. VIVA TRAP: Is a renal biopsy mandatory in every child who presents with microscopic hematuria and mild proteinuria during an acute episode of IgA Vasculitis?	NO. Renal biopsy is reserved for specific high-risk indications such as nephrotic-range proteinuria, persistent significant proteinuria (>0.5 mg/mg for >4 weeks), acute kidney injury, or suspected RPGN.

Evidence-Based Management & Pharmacotherapy

Question	Answer
1. What is the initial pharmacological management for a child with IgA Vasculitis presenting with mild proteinuria (UPCR between 0.2 and 1.0)?	1. ACE inhibitors (such as Enalapril) or ARBs (such as Losartan) are indicated. 2. They provide crucial antiproteinuric and long-term renoprotective effects.
2. What is the standard oral corticosteroid regimen recommended for children with HSP nephritis exhibiting severe proteinuria or ISKDC Grade III crescents (<50%)?	1. Oral Prednisolone is administered at a dosage of 2 mg/kg/day for 4 weeks. 2. This is followed by a tapered alternate-day regimen continuing for 3 to 6 months.
3. What is the emergency intravenous pulse steroid protocol for children with IgA Vasculitis presenting with severe crescentic glomerulonephritis (ISKDC Grade IV-V)?	1. Intravenous Methylprednisolone pulses are administered at a dosage of 30 mg/kg/day (maximum 1 g/day) for 3 consecutive days.
4. What are the two primary immunosuppressive agents combined with pulse steroids in children with severe ISKDC Grade IV-V crescentic HSP nephritis?	1. Intravenous Cyclophosphamide administered monthly (500–750 mg/m2 per dose for 6 pulses) OR oral Mycophenolate Mofetil (800–1200 mg/m2/day).
5. What is the primary mechanism of action of Mycophenolate Mofetil (MMF) when utilized in the management of severe immune-mediated IgA nephropathy?	1. MMF acts as a selective, non-competitive, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). 2. This suppresses the de novo synthesis of guanosine nucleotides, selectively inhibiting proliferation of T and B lymphocytes.
6. What essential baseline laboratory parameters must be monitored prior to and during therapy with intravenous Cyclophosphamide in pediatric glomerulonephritis?	1. Complete blood count with absolute neutrophil count to monitor for bone marrow suppression and leukopenia. 2. Serum creatinine and estimated GFR to adjust dosing for renal clearance.
7. What specific organ toxicity must be actively monitored during long-term or cumulative high-dose Cyclophosphamide therapy in children?	1. Gonadal toxicity and premature ovarian failure or azoospermia. 2. Hemorrhagic cystitis, requiring adequate hydration and concurrent administration of mesna when high doses are used.
8. What is the recommended duration of intravenous Cyclophosphamide pulse therapy in severe crescentic HSP nephritis according to standard pediatric nephrology protocols?	1. A total of 6 monthly intravenous pulses are standardly administered to induce sustained remission while limiting cumulative lifetime dose toxicity.
9. What pharmacological intervention is indicated for the management of severe, debilitating arthralgia or arthritis associated with acute IgA Vasculitis?	1. Simple analgesics such as paracetamol or short-course non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. 2. NSAIDs must be used cautiously and avoided if acute kidney injury or active GI bleeding is present.
10. What specific therapeutic intervention is required when severe gastrointestinal vasculitis leads to acute ileo-ileal intussusception in IgA Vasculitis?	1. Initial trial of hydrostatic or pneumatic enema reduction under fluoroscopic or ultrasound guidance, provided there is no evidence of bowel perforation or peritonitis. 2. Immediate surgical consultation for manual reduction or bowel resection if radiological reduction fails or ischemia is present.
11. What specific monitoring protocol for blood pressure and urinalysis is mandatory during the first 6 months following the onset of IgA Vasculitis to catch early nephritis?	1. Weekly testing for the first month. 2. Bi-weekly testing for the second and third months, and monthly testing up to 6 months post-onset.
12. What is the primary indication for performing a renal biopsy in a child with diagnosed IgA Vasculitis?	1. Nephrotic-range proteinuria, persistent proteinuria (UPCR >0.5-1.0 for >4 weeks), unexplained acute kidney injury, or suspected rapidly progressive glomerulonephritis (RPGN).
13. What dietary or supportive care measures are indicated during the acute phase of severe gastrointestinal IgA Vasculitis with abdominal pain and hematochezia?	1. Bowel rest with enteral fasting and intravenous fluid support during severe acute abdominal pain or bleeding episodes. 2. Gradual reintroduction of a bland diet once symptoms begin to clearly resolve.
14. What specific blood monitoring is required for patients receiving prolonged oral Mycophenolate Mofetil therapy for refractory HSP nephritis?	1. Regular complete blood counts to rule out pure red cell aplasia, leukopenia, or severe anemia. 2. Periodic liver function tests and monitoring for gastrointestinal intolerance or opportunistic viral infections.
15. VIVA TRAP: 6. VIVA TRAP: Can systemic corticosteroids be prescribed routinely to every child with uncomplicated cutaneous IgA Vasculitis to prevent the future development of renal involvement?	NO. Current pediatric guidelines confirm that early routine administration of systemic corticosteroids does not prevent the eventual onset of IgA vasculitis nephritis and is reserved for severe organ-threatening manifestations.
16. What is the precise pharmacological role of proton pump inhibitors (PPIs) in the acute management protocol of children with severe gastrointestinal IgAV?	1. They are administered prophylactically to prevent acute upper gastrointestinal mucosal stress ulceration, erosive gastritis, and upper GI bleeding exacerbated by high-dose systemic corticosteroid therapy.
17. What specific clinical response defines successful induction therapy in a patient treated with pulse steroids and immunosuppression for crescentic HSP nephritis?	1. Stabilization or improvement of estimated GFR, normalization of blood pressure, and a progressive reduction of proteinuria to non-nephrotic ranges (UPCR <0.2).
18. What long-term pharmacological strategy is indicated if a patient with IgA Vasculitis nephritis develops persistent hypertension despite resolution of acute systemic inflammation?	1. Continuation of long-term blockade of the renin-angiotensin-aldosterone system using ACE inhibitors or ARBs, combined with calcium channel blockers if blood pressure remains uncontrolled.
19. VIVA TRAP: 20. VIVA TRAP: Is therapeutic plasma exchange (plasmapheresis) considered a first-line mandatory therapy for all children presenting with mild microscopic hematuria during an IgAV flare?	NEVER. Plasmapheresis is strictly reserved as an adjunctive rescue therapy for life-threatening or refractory manifestations such as severe pulmonary hemorrhage or rapidly progressive crescentic glomerulonephritis unresponsive to pulse steroids and cyclophosphamide.

High-Yield VIVA TRAPs & Examiner Pitfalls

Question	Answer
1. VIVA TRAP: Should loop diuretics like Furosemide be initiated as the primary medical treatment for generalized lower limb edema caused by capillary leak and inflammation in acute IgA Vasculitis?	NEVER. Edema in acute IgA Vasculitis is primarily driven by inflammatory capillary permeability and soft-tissue vasculitis rather than true intravascular volume overload; diuretics are ineffective and risk aggravating renal hypoperfusion.
2. VIVA TRAP: Is it safe to prescribe strong non-steroidal anti-inflammatory drugs (NSAIDs) such as Ibuprofen for joint pain when a child with IgA Vasculitis has concurrent microscopic hematuria or borderline renal function?	NEVER. NSAIDs inhibit renal prostaglandins, significantly reducing glomerular filtration rate and risking acute kidney injury in a patient whose kidneys are already vulnerable to immune-complex deposition.
3. VIVA TRAP: Can live attenuated vaccines (such as MMR or Varicella) be administered safely to a child who is currently receiving high-dose oral corticosteroids or Mycophenolate Mofetil for severe HSP nephritis?	CONTRAINDICATED. Live attenuated vaccines must never be administered during active immunosuppressive therapy due to the high risk of disseminated, life-threatening vaccine-strain infections.
4. VIVA TRAP: Is routine skin biopsy mandatory before establishing the diagnosis of IgA Vasculitis in a child who presents with classical symmetrical palpable purpura over the lower limbs and buttocks?	NO. Skin biopsy is entirely unnecessary for diagnosis when classical palpable purpura is present alongside at least one auxiliary criterion (arthritis, abdominal pain, or renal involvement); it is reserved strictly for atypical presentations.
5. VIVA TRAP: Should prophylactic systemic antibiotics be routinely prescribed to all children presenting with IgA Vasculitis to eradicate an antecedent upper respiratory tract streptococcal infection?	NONE. Antibiotics are indicated only if there is a documented, active throat infection confirmed by culture or rapid antigen testing; routine prophylactic eradication does not alter the clinical course or prevent renal complications of IgAV.
6. VIVA TRAP: Is surgical exploration or laparotomy the immediate initial management choice for colicky abdominal pain in a child with IgA Vasculitis suspected of having bowel wall edema?	NEVER. Colicky abdominal pain in IgAV is primarily caused by submucosal edema and intramural hemorrhage; unnecessary surgical exploration must be avoided unless definitive complications like ileo-ileal intussusception or bowel perforation are proven.
7. VIVA TRAP: Can routine outpatient ambulation and sports activities be encouraged without restriction during the acute phase of severe cutaneous and articular IgA Vasculitis?	NO. Strict physical rest and avoidance of prolonged dependency of the lower limbs are strongly advised during the acute inflammatory phase to minimize the exacerbation of purpuric skin lesions and dependent edema.
8. VIVA TRAP: Is long-term prophylactic anticoagulant therapy (such as low-molecular-weight heparin) indicated for all children with IgA Vasculitis to prevent thrombotic complications of systemic vasculitis?	NONE. Thromboembolic complications are extremely rare in pediatric IgAV, and routine prophylactic anticoagulation is neither recommended nor justified given the bleeding risks associated with gastrointestinal vasculitis.
9. VIVA TRAP: Should diagnostic renal angiography be performed as a routine first-line investigation to confirm renal vascular inflammation in a child presenting with HSP nephritis?	NEVER. Renal angiography is highly invasive, carries significant vascular complication risks, and is completely unnecessary; diagnosis and grading of HSP nephritis are established entirely through non-invasive urinalysis and targeted renal biopsy.
10. VIVA TRAP: Is intravenous immunoglobulin (IVIG) considered a standard first-line induction agent for the management of severe crescentic HSP nephritis?	NO. While IVIG is occasionally utilized in refractory thrombocytopenic purpura or severe cutaneous vasculitis, it plays no role as a standard first-line induction therapy for crescentic glomerulonephritis in IgAV.
11. VIVA TRAP: Can routine systemic corticosteroids completely prevent the recurrence of cutaneous purpura or arthralgia flares after the medication is tapered or stopped?	NO. Systemic corticosteroids may successfully control acute symptomatic inflammation, but they do not alter the natural relapsing-remitting multiphasic disease course characteristic of IgA Vasculitis.
12. VIVA TRAP: Should diagnostic lumbar puncture and neuroimaging be performed routinely on every child presenting with standard lower limb palpable purpura and joint pain?	NONE. Central nervous system involvement in IgAV (central nervous system vasculitis) is rare and presents with focal neurological deficits, seizures, or encephalopathy; invasive neurodiagnostics are strictly reserved for symptomatic patients.
13. VIVA TRAP: Is it appropriate to discharge a child diagnosed with IgA Vasculitis from follow-up care immediately after the skin rash and joint swelling completely resolve within the first two weeks?	NEVER. Because up to 90% of renal complications develop within the first 6 to 8 weeks and can remain completely asymptomatic initially, every child requires a mandatory 6-month structured blood pressure and urinalysis surveillance protocol.
14. VIVA TRAP: Should high-dose systemic corticosteroids be administered indefinitely as maintenance therapy to prevent long-term chronic kidney disease progression in healed IgAV nephritis?	NEVER. Prolonged maintenance systemic corticosteroids carry severe risks of growth retardation, Cushingoid facies, hypertension, and immunosuppression; therapy must be tapered strictly according to clinical remission and proteinuria normalization.
15. VIVA TRAP: Can a normal serum creatinine level at initial presentation of IgA Vasculitis reliably exclude significant underlying histological glomerular crescent formation on renal biopsy?	NO. Severe crescentic glomerulonephritis (ISKDC Grade III or IV) with heavy proteinuria and active crescents can frequently coexist with a completely normal serum creatinine due to compensatory hyperfiltration in the unaffected glomeruli.
16. VIVA TRAP: Is routine screening for hypercoagulability (such as protein C, protein S, and antithrombin III deficiency) mandatory during the initial diagnostic evaluation of uncomplicated IgA Vasculitis?	NONE. IgA Vasculitis is an immune-complex mediated small-vessel leukocytoclastic vasculitis, not a primary thrombophilia; hypercoagulability workups are unnecessary unless atypical thrombotic events occur.